Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF – Get Free Report)’s share price passed above its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $20.28 and traded as high as $22.2775. Hikma Pharmaceuticals shares last traded at $22.2775, with a volume of 200 shares changing hands.
Analyst Upgrades and Downgrades
Separately, Citigroup started coverage on shares of Hikma Pharmaceuticals in a research report on Thursday, July 16th. They set a “buy” rating on the stock. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Hikma Pharmaceuticals presently has a consensus rating of “Hold”.
Read Our Latest Report on HKMPF
Hikma Pharmaceuticals Stock Up 3.3%
About Hikma Pharmaceuticals
Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.
Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.
Further Reading
- Five stocks we like better than Hikma Pharmaceuticals
- Take-Two’s Q1 Results Leave GTA 6 Bulls Stuck in the Fog of War
- AI Cold War Catches Light: Federal Friction in the Server Rack
- 3 Stocks Whose Charts May Be Signaling the Next Big Move
- Quantum Earnings Week: Winners and Losers Are Finally Emerging
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
